info
Grupos de Google ya no admite nuevas publicaciones ni suscripciones de Usenet. El contenido anterior sigue siendo visible.
Dismiss
Research Assistant at University of Cambridge
Visto 1 vez
Saltar al primer mensaje no leído
Ema Shollenberger
7 feb 2019, 15:49:517/2/19
a emap...@gmail.com
Applications are invited for a Research Assistant to join the team of Dr Emmanouil Metzakopian, in the newly established UK Dementia Research Institute (UK DRI) Centre at the University of Cambridge, Cambridge Biomedical Campus, Cambridge UK to work on CRISPR screening and single cell analysis of iPSC-derived neurons.
The mission of the UK DRI at the University of Cambridge, is to create a collaborative, inter-disciplinary Centre, combining world-leading expertise unique to Cambridge from chemistry, biophysics and structural biology with internationally leading research in the cell biology of neurodegeneration. This environment will enable creative and innovative approaches to the study of neurodegenerative disease and drive a gear change in our scientific understanding.
The scientific focus of the Centre is on understanding mechanisms involved in the earliest stages of neurodegenerative disease in order, ultimately, to deliver therapeutic targets with the greatest potential to prevent dementia. Three Foundation programmes led by DRI professors are complemented by three new programmes led by DRI Fellows (including Dr. Metzakopian) to develop this field.
We are now looking for a Research Assistant to join the laboratory of Dr. Emmanouil Metzakopian. The focus of the Metzakopian lab is on insights into novel neuroprotective mechanisms in neurodegeneration that provide new targets for treatments of these disorders.
The project is funded by Open Targets, as a joint venture between Dr. Metzakopian at the UK DRI and Open Targets partners including the Wellcome Sanger Institute, the European Bioinformatics Institute, GSK, Biogen, Takeda, Cellgene and Sanofi. The aim is to identify and validate therapeutic targets for neurodevelopmental and psychiatric disorders with a known genetic basis, by comparing molecular profiles of disease states to the response profiles of drugs and gene knockouts using CRISPR-Cas9. This study leverages substantial genetic and functional resources within Open Targets.
Education to graduate level in a relevant subject is required. Knowledge of techniques in cell and molecular biology is essential although training in all relevant techniques will be provided.
To learn more about Open Targets please visit: www.opentargets.org
For further enquiries please contact: em...@medschl.cam.ac.uk
Fixed-term: The funds for this post are available until 1 January 2022 in the first instance.
For instructions on how to apply, please refer to: http://bit.ly/2GfBvfO
The mission of the UK DRI at the University of Cambridge, is to create a collaborative, inter-disciplinary Centre, combining world-leading expertise unique to Cambridge from chemistry, biophysics and structural biology with internationally leading research in the cell biology of neurodegeneration. This environment will enable creative and innovative approaches to the study of neurodegenerative disease and drive a gear change in our scientific understanding.
The scientific focus of the Centre is on understanding mechanisms involved in the earliest stages of neurodegenerative disease in order, ultimately, to deliver therapeutic targets with the greatest potential to prevent dementia. Three Foundation programmes led by DRI professors are complemented by three new programmes led by DRI Fellows (including Dr. Metzakopian) to develop this field.
We are now looking for a Research Assistant to join the laboratory of Dr. Emmanouil Metzakopian. The focus of the Metzakopian lab is on insights into novel neuroprotective mechanisms in neurodegeneration that provide new targets for treatments of these disorders.
The project is funded by Open Targets, as a joint venture between Dr. Metzakopian at the UK DRI and Open Targets partners including the Wellcome Sanger Institute, the European Bioinformatics Institute, GSK, Biogen, Takeda, Cellgene and Sanofi. The aim is to identify and validate therapeutic targets for neurodevelopmental and psychiatric disorders with a known genetic basis, by comparing molecular profiles of disease states to the response profiles of drugs and gene knockouts using CRISPR-Cas9. This study leverages substantial genetic and functional resources within Open Targets.
Education to graduate level in a relevant subject is required. Knowledge of techniques in cell and molecular biology is essential although training in all relevant techniques will be provided.
To learn more about Open Targets please visit: www.opentargets.org
For further enquiries please contact: em...@medschl.cam.ac.uk
Fixed-term: The funds for this post are available until 1 January 2022 in the first instance.
For instructions on how to apply, please refer to: http://bit.ly/2GfBvfO
0 mensajes nuevos